The post hoc analysis of PARAGON-HF assessed the efficacy of sacubitril/valsartan, compared with valsartan, according to frailty status in patients with heart failure (HF) with preserved fraction (HFpEF). Frailty is a common issue, with patients less likely to receive pharmacological therapy due to a less favourable benefit/risk profile. In this touchCARDIO interview, we speak with Dr Jawad Haider Butt (Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark) to discuss the post-hoc analysis of PARAGON-HF data and the impact of patient frailty on clinical outcomes.
The abstract entitled ‘Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What are the challenges in the treatment of frail patients with heart failure (HF)? (0:18)
- Can you give us an overview of the PARAGON-HF trial? (2:00)
- Could you tell us a little about the post-hoc analysis of PARAGON-HF data, and the parameters used to assess frailty? (2:44)
- How were clinical outcomes affected by patient frailty? (4:05)
- What did the PARAGON-HF teach us about the efficacy and safety of sacubitril/valsartan, in patients with HF with preserved fraction (HFpEF)? (5:03)
- How can these findings be used to optimise treatment decisions in patients with HFpEF? (6:08)
Disclosures: Jawad Haider Butt is on the advisory board for Bayer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
